ClinicalTrials.gg
CompletedNCT04828993Updated Mar 12, 2024Results posted

The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients

A Phase 4 interventional study of tafamidis meglumine in Transthyretin Amyloid Polyneuropathy (ATTR-PN), sponsored by Pfizer. Completed at 9 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Amyloid Neuropathies, Familial with a site in China — 8 open to participants now, 8 under way, none of them phase 3. Amyloid Neuropathies, Familial · China.

Started
2021
the only one that year
Phase 4
2 of 10
1 open now
Registered
1st of 10
by date
Lead sponsor
1 of 10
Pfizer

Among the 10 studies in Amyloid Neuropathies, Familial with a site in China, this one is the only one that started in 2021, is one of 2 in phase 4, and was the 1st registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

8 of the 10 studies in Amyloid Neuropathies, Familial with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Amyloid Neuropathies, Familial with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open-label, multicenter study designed to evaluate the efficacy, safety, tolerability as well as pharmacodynamics of tafamidis meglumine in ATTR-PN participants in China.

Approximately 10-15 participants are planned to be enrolled. All enrolled participants will receive oral tafamidis meglumine 20 mg soft capsules once daily for 72 weeks (18 months).

Read the detailed description

This is a single-arm, open-label, multicenter study designed to evaluate the efficacy, safety, tolerability as well as pharmacodynamics of tafamidis meglumine in ATTR-PN participants in China.

All enrolled participants will receive oral tafamidis meglumine 20 mg soft capsules once daily starting on Day 1. Clinical visits will be scheduled at Baseline (Day 1) and at Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60 and Week 72. At Week 36 and Week 60 site visit, assessment of adverse events, safety related lab testings, concomitant medications and investigational product compliance will be scheduled. Every 6 weeks (do not exceed 7 weeks since last confirmation) telephone contacts will be made during visits in which no investigative site visits are scheduled for assessment of adverse events, concomitant medications and investigational product compliance (between Week 12 and 24, between Week 24 and 36, between Week 36 and 48, between Week 48 and 60, and between Week 60 and 72).

03

Conditions studied

  • Transthyretin Amyloid Polyneuropathy (ATTR-PN)

Keywords

  • tafamidis meglumine
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants between the ages of 18 and 80 years.
  2. Participants have amyloid documented by
  3. Participants must have a TTR mutation that is associated with ATTR-PN.
  4. Participants have peripheral and/or autonomic neuropathy
  5. Stages of disease according to symptom severity-stage I.

Exclusion criteria

Exclusion Criteria:

  1. Other acute or chronic medical or psychiatric condition including recent or active suicidal ideation or behavior or laboratory abnormality, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  2. Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs.
  3. Use of diflunisal, tauroursodeoxycholate, doxycycline, inotersen, patisiran or any other TTR stabilizing agent, or experimental interventions for familial amyloidosis within 30 days prior to the study entry and/or during study participation. Participants who are taking or who have previously taken tafamidis.

    Prior/Concurrent Clinical Study Experience:

  4. Previous administration with an drug within 30 days or 5 half lives preceding the first dose of investigational product used in this study (whichever is longer).
  5. Participant has primary (light chain) or secondary amyloidosis.
  6. If female, participant is pregnant or breast feeding, or plans to be pregnant or breast feeding in the next 18 months.
  7. Participant has received prior liver or any other organ except cornea transplantation.
  8. Participant requires significant assistance with ambulation or is wheel chair bound.
  9. Participants with cardiomyopathy specific TTR mutations.
  10. Participant has other causes of sensorimotor neuropathy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Tafamidis treatment arm

    Chinese patients diagnosed with ATTR-PN treated with tafamidis 20mg once daily oral administration for 72 weeks (18 months).

    Drug: tafamidis meglumine

Interventions

  • Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).

    Also known as: Vyndaqel

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Neuropathy Impairment Score-lower Limb (NIS-LL) Total Score at Week 72

    NIS-LL: assess muscle weakness, reflexes, sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae); sensation (touch pressure, pin-prick, vibration, joint position) scored 0 = normal, 1 = decreased, or 2 = absent. Total possible NIS-LL score range 0-88, high score = more impairment. Components of muscle weakness are scored to eight levels: 0 = Normal, 1 = 25% Weak, 2 = 50% Weak, 3 = 75% Weak, 3.25 = Move against gravity, 3.5 = Movement, gravity eliminated, 3.75 = Muscle flicker, no movement, 4 = Paralysis.

    Time frame: Baseline, Week 72

Secondary outcomes

  1. Change From Baseline in Neuropathy Impairment Score-lower Limb (NIS-LL) Total Score at Weeks 24, and 48

    NIS-LL: assess muscle weakness, reflexes, sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae); sensation (touch pressure, pin-prick, vibration, joint position) scored 0 = normal, 1 = decreased, or 2 = absent. Total possible NIS-LL score range 0-88, high score = more impairment. Components of muscle weakness are scored to eight levels: 0 = Normal, 1 = 25% Weak, 2 = 50% Weak, 3 = 75% Weak, 3.25 = Move against gravity, 3.5 = Movement, gravity eliminated, 3.75 = Muscle flicker, no movement, 4 = Paralysis.

    Time frame: Baseline, Week 24, Week 48

  2. Change From Baseline in Total Quality of Life (TQOL) of Norfolk Quality of Life - Diabetic Neuropathy (Norfolk QOL-DN) at Weeks 24, 48, and 72

    Norfolk QOL-DN: 35-item participant-rated questionnaire assess the impact of neuropathy on the quality of life of participants diagnosed with transthyretin amyloid (ATTR). Scoring is based on 35 questions that yield a TQOL as well as 5 subscale scores: activities of daily living, large fiber neuropathy/physical functioning, small fiber neuropathy, autonomic neuropathy, and symptoms. TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.

    Time frame: Baseline, Week 24, Week 48, Week 72

  3. Change From Baseline in 5 Domains of Norfolk QOL-DN at Weeks 24, 48, and 72

    Norfolk QOL-DN: 35-item participant-rated questionnaire assess the impact of neuropathy on the quality of life of participants diagnosed with transthyretin amyloid (ATTR). It is summarized in 5 domains: (1) Activities of daily living (score ranges from 0 to 20, where higher score=worse quality of life); (2) Large fiber neuropathy/physical functioning (score ranges from -2 to 58, where higher score=worse condition); (3) Small fiber neuropathy (score ranges from 0 to 16, where higher score=worse condition); (4) Autonomic neuropathy (score ranges from 0 to 12, where higher score=worse condition) and (5) Symptoms (score ranges from 0 to 32, where higher score=less symptoms of disease). Total possible score range= -2 to 138, where higher score=worse quality of life.

    Time frame: Baseline, Week 24, Week 48, Week 72

  4. Change From Baseline in Modified Body Mass Index (mBMI) at Weeks 4, 8, 12, 24, 36, 48, and 72

    BMI is calculated by weight divided by height squared and measured as kilogram per square meter (kg/m\^2). mBMI is calculated by multiplying BMI by serum albumin levels \[gram/liter (g/L)\]. mBMI is measured as kg/m\^2\*g/L. A progressive decline in mBMI indicates worsening of disease severity.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, and 72

  5. Change From Baseline in Physical Component Summary and Mental Component Summary of 36-Item Short Form Survey (SF-36) at Weeks 24, 48, and 72

    The SF-36 is a participant administered scale assessing general quality of life. It consists of self-administered 36-item questionnaire that measured 8 health domains: physical function, role-physical, bodily pain, general health, vitality, social function, role-emotional, and mental health. These 8 domains are also summarized as physical and mental component scores. The score for each domain and component score is the mean of the individual question scores, which are scaled from 0 (minimum) to 100 (maximum), where high scores in each dimension and high overall scores indicate a better quality of life.

    Time frame: Baseline, Weeks 24, 48, and 72

  6. Change From Baseline in EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Index Score at Weeks 24, 48, and 72

    EQ-5D-5L: standardized participant (aged \>17 years) completed questionnaire consists of 2 components: a health state profile and an optional VAS. EQ-5D health state profile has 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. Responses to 5 dimensions comprise a health state/a single utility index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses on each of 5 dimensions) has a unique predefined utility index value assigned to it, by EuroQol. Chinese value sets (with all possible health states) is used for adults in the study, range from -0.391 to 1. Higher (positive) scores = better health state.

    Time frame: Baseline, Weeks 24, 48, and 72

  7. Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)

    An adverse event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment emergent adverse event is defined as any adverse event started after the first dose. The TEAEs were collected until Week 77.

    Time frame: Baseline up to Week 77

  8. Number of Participants With Categorical Vital Signs Data

    Vital signs categorical criteria: 1) pulse rate \<40 beats per minute (bpm), or \>120 bpm; 2) standing diastolic blood pressure (BP) \<50 mmHg, or increase ≥20 mmHg, or decrease ≥20 mmHg; 3) standing systolic BP \<90 mmHg, or increase ≥30 mmHg, or decrease ≥30 mmHg; 4) supine diastolic BP \<50 mmHg, or increase ≥20 mmHg, or decrease ≥20 mmHg; 5) supine systolic BP \<90 mmHg, or increase ≥30 mmHg, or decrease ≥30 mmHg.

    Time frame: Baseline up to Week 72

  9. Number of Participants With Categorical Electrocardiogram (ECG) Data

    ECG categorical criteria: 1) ECG mean heart rate \<40 beats/minute, or \>120 beats/minute; 2) PR interval not otherwise specified ≥300 milliseconds (msec), or baseline \>200 msec and %increase ≥25%/ baseline ≤200 msec and %increase ≥50% (% change ≥25/50%); 3) QRS interval not otherwise specified ≥140 msec, or %change ≥50%; 4) QT interval not otherwise specified ≥500 msec; 5) corrected QT (QTc) interval not otherwise specified ≥450 and \<480 msec, or ≥480 and \<500 msec, or ≥500 msec; or change ≥30 and \<60 msec, or change ≥60 msec.

    Time frame: Baseline up to Week 72

  10. Number of Participants With Clinically Significant Echocardiography (ECHO) Value Related to Primary Diagnosis (Transthyretin Amyloidosis [ATTR]) at Baseline, Weeks 24, 48, and 72

    Clinically significant ECHO findings include: left ventricular (LV) posterior wall thickness greater than or equal to (\>=)13 mm, LV septal thickness \>= 13 mm, right ventricular thickness \>= 7 mm, ratio of peak mitral early diastolic and atrial contraction velocity (E/A ratio) \>= 2, prime septal (E/E) \>15, ejection fraction \< 50 percent (%), E deceleration time \<= 150 millisecond (ms), isovolumic relaxation time (IVRT) \<= 70 ms, any valve thickening (\> trace regurgitation in mitral, aortic, pulmonary, or tricuspid valves), abnormal respiratory variation of inferior vena cava, pericardial effusion.

    Time frame: Baseline, Weeks 24, 48, and 72

  11. Number of Participants With Clinical Laboratory Abnormalities

    Protocol-required safety laboratory assessments include: Lymphocytes \<0.8 × LLN; Neutrophils \<0.8 × LLN, or \>1.2 × ULN; Basophils \>1.2 × ULN; Activated Partial Thromboplastin Time \>1.1 × ULN; Prothrombin Time \>1.1 × ULN; Prothrombin International Normalized Ratio \>1.1 × ULN; Bilirubin \>1.5 × ULN; Urate \> 1.2 × ULN; Cholesterol \>1.3 × ULN; Potassium \<0.9 × LLN; Phosphate \>1.2 × ULN; Bicarbonate \>1.1 × ULN; Thyroid Stimulating Hormone \>1.2 × ULN; URINE Protein ≥1; URINE Hemoglobin ≥1; Nitrite ≥1; URINE Erythrocytes ≥20; Epithelial Cells ≥6; and Casts \>1.

    Time frame: Baseline up to Week 72

  12. Transthyretin (TTR) Concentrations on Day 1 (Baseline), and at Weeks 8, 12, 24, 48, and 72

    The TTR (also referred to as pre-albumin) concentrations were determined as pharmacodynamic (PD) biomarkers.

    Time frame: Baseline, Weeks 8, 12, 24, 48, and 72

  13. TTR Stabilization and Percentage and 95% CI of Responders in TTR Stabilization at Post Baseline Visit

    The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration (post-denaturation) to the measured TTR concentration (pre-denaturation). Percent Stabilization (%) is the difference between the dosed FOI and the baseline FOI expressed as a percentage of the baseline FOI. Responder was the participant who achieved TTR stabilization (ie, who had been TTR stabilized). Percentage of responders was number of responders / number of evaluable (i.e., analyzed) participants.

    Time frame: Weeks 8, 12, 24, 48, and 72

07

Results

Posted Mar 12, 2024

Participant flow

Disposition Phase: TREATMENT
Participant flow — Disposition Phase: TREATMENT
MilestoneTafamidis Meglumine 20 mg Once Daily (QD)
Started15
Completed15
Not completed0
Disposition Phase: FOLLOW-UP
Participant flow — Disposition Phase: FOLLOW-UP
MilestoneTafamidis Meglumine 20 mg Once Daily (QD)
Started15
Completed15
Not completed0

Outcome measures

PrimaryChange From Baseline in Neuropathy Impairment Score-lower Limb (NIS-LL) Total Score at Week 72

NIS-LL: assess muscle weakness, reflexes, sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae); sensation (touch pressure, pin-prick, vibration, joint position) scored 0 = normal, 1 = decreased, or 2 = absent. Total possible NIS-LL score range 0-88, high score = more impairment. Components of muscle weakness are scored to eight levels: 0 = Normal, 1 = 25% Weak, 2 = 50% Weak, 3 = 75% Weak, 3.25 = Move against gravity, 3.5 = Movement, gravity eliminated, 3.75 = Muscle flicker, no movement, 4 = Paralysis.

Time frame:
Baseline, Week 72
Reported as:
Median · Units on a scale
Change From Baseline in Neuropathy Impairment Score-lower Limb (NIS-LL) Total Score at Week 72
Units on a scaleTafamidis Meglumine 20 mg Once Daily (QD)
Change From Baseline in Neuropathy Impairment Score-lower Limb (NIS-LL) Total Score at Week 722.3 (-3.0 to 46.0)
SecondaryChange From Baseline in Neuropathy Impairment Score-lower Limb (NIS-LL) Total Score at Weeks 24, and 48

NIS-LL: assess muscle weakness, reflexes, sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae); sensation (touch pressure, pin-prick, vibration, joint position) scored 0 = normal, 1 = decreased, or 2 = absent. Total possible NIS-LL score range 0-88, high score = more impairment. Components of muscle weakness are scored to eight levels: 0 = Normal, 1 = 25% Weak, 2 = 50% Weak, 3 = 75% Weak, 3.25 = Move against gravity, 3.5 = Movement, gravity eliminated, 3.75 = Muscle flicker, no movement, 4 = Paralysis.

Time frame:
Baseline, Week 24, Week 48
Reported as:
Median · Units on a scale
Change From Baseline in Neuropathy Impairment Score-lower Limb (NIS-LL) Total Score at Weeks 24, and 48
Units on a scaleTafamidis Meglumine 20 mg Once Daily (QD)
Change From Baseline in Neuropathy Impairment Score-lower limb (NIS-LL) Total Score at Week 243.0 (-20.0 to 20.0)
Change From Baseline in Neuropathy Impairment Score-lower limb (NIS-LL) Total Score at Week 488.0 (-13.5 to 18.0)
SecondaryChange From Baseline in Total Quality of Life (TQOL) of Norfolk Quality of Life - Diabetic Neuropathy (Norfolk QOL-DN) at Weeks 24, 48, and 72

Norfolk QOL-DN: 35-item participant-rated questionnaire assess the impact of neuropathy on the quality of life of participants diagnosed with transthyretin amyloid (ATTR). Scoring is based on 35 questions that yield a TQOL as well as 5 subscale scores: activities of daily living, large fiber neuropathy/physical functioning, small fiber neuropathy, autonomic neuropathy, and symptoms. TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.

Time frame:
Baseline, Week 24, Week 48, Week 72
Reported as:
Median · Units on a scale
Change From Baseline in Total Quality of Life (TQOL) of Norfolk Quality of Life - Diabetic Neuropathy (Norfolk QOL-DN) at Weeks 24, 48, and 72
Units on a scaleTafamidis Meglumine 20 mg Once Daily (QD)
Change From Baseline in TQOL of Norfolk QOL-DN at Week 24-1.00 (-26.00 to 54.00)
Change From Baseline in TQOL of Norfolk QOL-DN at Week 482.00 (-26.00 to 63.00)
Change From Baseline in TQOL of Norfolk QOL-DN at Week 728.00 (-11.00 to 74.00)
SecondaryChange From Baseline in 5 Domains of Norfolk QOL-DN at Weeks 24, 48, and 72

Norfolk QOL-DN: 35-item participant-rated questionnaire assess the impact of neuropathy on the quality of life of participants diagnosed with transthyretin amyloid (ATTR). It is summarized in 5 domains: (1) Activities of daily living (score ranges from 0 to 20, where higher score=worse quality of life); (2) Large fiber neuropathy/physical functioning (score ranges from -2 to 58, where higher score=worse condition); (3) Small fiber neuropathy (score ranges from 0 to 16, where higher score=worse condition); (4) Autonomic neuropathy (score ranges from 0 to 12, where higher score=worse condition) and (5) Symptoms (score ranges from 0 to 32, where higher score=less symptoms of disease). Total possible score range= -2 to 138, where higher score=worse quality of life.

Time frame:
Baseline, Week 24, Week 48, Week 72
Reported as:
Median · Units on a scale
Change From Baseline in 5 Domains of Norfolk QOL-DN at Weeks 24, 48, and 72
Units on a scaleTafamidis Meglumine 20 mg Once Daily (QD)
Change From Baseline in Physical Functioning/Large Fiber Domain of Norfolk QOL-DN at Week 24-3.00 (-22.00 to 28.00)
Change From Baseline in Physical Functioning/Large Fiber Domain of Norfolk QOL-DN at Week 482.00 (-13.00 to 38.00)
Change From Baseline in Physical Functioning/Large Fiber Domain of Norfolk QOL-DN at Week 724.00 (-10.00 to 39.00)
Change From Baseline in Activities of Daily Living Domain of Norfolk QOL-DN at Week 240.00 (-4.00 to 12.00)
Change From Baseline in Activities of Daily Living Domain of Norfolk QOL-DN at Week 481.00 (-4.00 to 15.00)
Change From Baseline in Activities of Daily Living Domain of Norfolk QOL-DN at Week 723.00 (-2.00 to 15.00)
Change From Baseline in Symptoms Domain of Norfolk QOL-DN at Week 241.00 (-13.00 to 9.00)
Change From Baseline in Symptoms Domain of Norfolk QOL-DN at Week 482.00 (-6.00 to 9.00)
Change From Baseline in Symptoms Domain of Norfolk QOL-DN at Week 722.00 (-2.00 to 23.00)
Change From Baseline in Small Fiber Domain of Norfolk QOL-DN at Week 240.00 (-3.00 to 6.00)
Change From Baseline in Small Fiber Domain of Norfolk QOL-DN at Week 481.00 (-2.00 to 9.00)
Change From Baseline in Small Fiber Domain of Norfolk QOL-DN at Week 723.00 (-3.00 to 10.00)
Change From Baseline in Autonomic Domain of Norfolk QOL-DN at Week 240.00 (-4.00 to 3.00)
Change From Baseline in Autonomic Domain of Norfolk QOL-DN at Week 480.00 (-5.00 to 4.00)
Change From Baseline in Autonomic Domain of Norfolk QOL-DN at Week 722.00 (-5.00 to 6.00)
SecondaryChange From Baseline in Modified Body Mass Index (mBMI) at Weeks 4, 8, 12, 24, 36, 48, and 72

BMI is calculated by weight divided by height squared and measured as kilogram per square meter (kg/m\^2). mBMI is calculated by multiplying BMI by serum albumin levels \[gram/liter (g/L)\]. mBMI is measured as kg/m\^2\*g/L. A progressive decline in mBMI indicates worsening of disease severity.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, and 72
Reported as:
Median · kg/m^2*g/L
Change From Baseline in Modified Body Mass Index (mBMI) at Weeks 4, 8, 12, 24, 36, 48, and 72
kg/m^2*g/LTafamidis Meglumine 20 mg Once Daily (QD)
Change From Baseline in mBMI at Week 4-5.9 (-87.2 to 95.5)
Change From Baseline in Modified Body Mass Index (mBMI) at Week 822.3 (-101.2 to 219.7)
Change From Baseline in Modified Body Mass Index (mBMI) at Week 129.2 (-39.0 to 199.3)
Change From Baseline in Modified Body Mass Index (mBMI) at Week 2421.8 (-132.8 to 179.1)
Change From Baseline in Modified Body Mass Index (mBMI) at Week 3637.0 (-79.3 to 207.7)
Change From Baseline in Modified Body Mass Index (mBMI) at Week 4841.4 (-130.2 to 152.6)
Change From Baseline in Modified Body Mass Index (mBMI) at Week 729.4 (-161.8 to 179.5)
SecondaryChange From Baseline in Physical Component Summary and Mental Component Summary of 36-Item Short Form Survey (SF-36) at Weeks 24, 48, and 72

The SF-36 is a participant administered scale assessing general quality of life. It consists of self-administered 36-item questionnaire that measured 8 health domains: physical function, role-physical, bodily pain, general health, vitality, social function, role-emotional, and mental health. These 8 domains are also summarized as physical and mental component scores. The score for each domain and component score is the mean of the individual question scores, which are scaled from 0 (minimum) to 100 (maximum), where high scores in each dimension and high overall scores indicate a better quality of life.

Time frame:
Baseline, Weeks 24, 48, and 72
Reported as:
Median · Units on a scale
Change From Baseline in Physical Component Summary and Mental Component Summary of 36-Item Short Form Survey (SF-36) at Weeks 24, 48, and 72
Units on a scaleTafamidis Meglumine 20 mg Once Daily (QD)
Change from Baseline in Physical Component Summary at Week 24-2.15 (-9.29 to 11.84)
Change from Baseline in Physical Component Summary at Week 48-0.12 (-12.13 to 12.08)
Change from Baseline in Physical Component Summary at Week 72-1.60 (-17.61 to 8.89)
Change from Baseline in Mental Component Summary at Week 241.21 (-9.56 to 19.30)
Change from Baseline in Mental Component Summary at Week 48-2.56 (-31.69 to 9.36)
Change from Baseline in Mental Component Summary at Week 72-6.10 (-31.85 to 8.17)
SecondaryChange From Baseline in EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Index Score at Weeks 24, 48, and 72

EQ-5D-5L: standardized participant (aged \>17 years) completed questionnaire consists of 2 components: a health state profile and an optional VAS. EQ-5D health state profile has 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. Responses to 5 dimensions comprise a health state/a single utility index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses on each of 5 dimensions) has a unique predefined utility index value assigned to it, by EuroQol. Chinese value sets (with all possible health states) is used for adults in the study, range from -0.391 to 1. Higher (positive) scores = better health state.

Time frame:
Baseline, Weeks 24, 48, and 72
Reported as:
Median · Units on a scale
Change From Baseline in EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Index Score at Weeks 24, 48, and 72
Units on a scaleTafamidis Meglumine 20 mg Once Daily (QD)
Change from Baseline in EQ-5D-5L Index Score at Week 240.00 (-0.50 to 0.22)
Change from Baseline in EQ-5D-5L Index Score at Week 48-0.05 (-0.51 to 0.11)
Change from Baseline in EQ-5D-5L Index Score at Week 72-0.16 (-0.75 to 0.11)
SecondaryNumber of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)

An adverse event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment emergent adverse event is defined as any adverse event started after the first dose. The TEAEs were collected until Week 77.

Time frame:
Baseline up to Week 77
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
ParticipantsTafamidis Meglumine 20 mg Once Daily (QD)
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)13
SecondaryNumber of Participants With Categorical Vital Signs Data

Vital signs categorical criteria: 1) pulse rate \<40 beats per minute (bpm), or \>120 bpm; 2) standing diastolic blood pressure (BP) \<50 mmHg, or increase ≥20 mmHg, or decrease ≥20 mmHg; 3) standing systolic BP \<90 mmHg, or increase ≥30 mmHg, or decrease ≥30 mmHg; 4) supine diastolic BP \<50 mmHg, or increase ≥20 mmHg, or decrease ≥20 mmHg; 5) supine systolic BP \<90 mmHg, or increase ≥30 mmHg, or decrease ≥30 mmHg.

Time frame:
Baseline up to Week 72
Reported as:
Count of participants · Participants
Number of Participants With Categorical Vital Signs Data
ParticipantsTafamidis Meglumine 20 mg Once Daily (QD)
Pulse rate <40 bpm0
Pulse rate >120 bpm0
Standing diastolic BP <50 mmHg4
Standing diastolic BP increase ≥20 mmHg3
Standing diastolic BP decrease ≥20 mmHg0
Standing systolic BP <90 mmHg6
Standing systolic BP increase ≥30 mmHg5
Standing systolic BP decrease ≥30 mmHg3
Supine diastolic BP <50 mmHg0
Supine diastolic BP increase ≥20 mmHg2
Supine diastolic BP decrease ≥20 mmHg2
Supine systolic BP <90 mmHg0
Supine systolic BP increase ≥30 mmHg1
Supine systolic BP decrease ≥30 mmHg1
SecondaryNumber of Participants With Categorical Electrocardiogram (ECG) Data

ECG categorical criteria: 1) ECG mean heart rate \<40 beats/minute, or \>120 beats/minute; 2) PR interval not otherwise specified ≥300 milliseconds (msec), or baseline \>200 msec and %increase ≥25%/ baseline ≤200 msec and %increase ≥50% (% change ≥25/50%); 3) QRS interval not otherwise specified ≥140 msec, or %change ≥50%; 4) QT interval not otherwise specified ≥500 msec; 5) corrected QT (QTc) interval not otherwise specified ≥450 and \<480 msec, or ≥480 and \<500 msec, or ≥500 msec; or change ≥30 and \<60 msec, or change ≥60 msec.

Time frame:
Baseline up to Week 72
Reported as:
Count of participants · Participants
Number of Participants With Categorical Electrocardiogram (ECG) Data
ParticipantsTafamidis Meglumine 20 mg Once Daily (QD)
ECG mean heart rate <40 beats/minute0
ECG mean heart rate >120 beats/minute0
PR interval not otherwise specified ≥300 milliseconds (msec)0
PR interval not otherwise specified % change ≥25/50%0
QRS interval not otherwise specified ≥140 msec1
QRS interval not otherwise specified %change ≥50%1
QT interval not otherwise specified ≥500 msec0
corrected QT (QTc) interval not otherwise specified ≥450 and <480 msec9
corrected QT (QTc) interval not otherwise specified ≥480 and <500 msec7
corrected QT (QTc) interval not otherwise specified ≥500 msec3
corrected QT (QTc) interval not otherwise specified change ≥30 and <60 msec5
corrected QT (QTc) interval not otherwise specified change ≥60 msec1
SecondaryNumber of Participants With Clinically Significant Echocardiography (ECHO) Value Related to Primary Diagnosis (Transthyretin Amyloidosis [ATTR]) at Baseline, Weeks 24, 48, and 72

Clinically significant ECHO findings include: left ventricular (LV) posterior wall thickness greater than or equal to (\>=)13 mm, LV septal thickness \>= 13 mm, right ventricular thickness \>= 7 mm, ratio of peak mitral early diastolic and atrial contraction velocity (E/A ratio) \>= 2, prime septal (E/E) \>15, ejection fraction \< 50 percent (%), E deceleration time \<= 150 millisecond (ms), isovolumic relaxation time (IVRT) \<= 70 ms, any valve thickening (\> trace regurgitation in mitral, aortic, pulmonary, or tricuspid valves), abnormal respiratory variation of inferior vena cava, pericardial effusion.

Time frame:
Baseline, Weeks 24, 48, and 72
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Echocardiography (ECHO) Value Related to Primary Diagnosis (Transthyretin Amyloidosis [ATTR]) at Baseline, Weeks 24, 48, and 72
ParticipantsTafamidis Meglumine 20 mg Once Daily (QD)
Number of Participants at Baseline9
Number of Participants at Week 2411
Number of Participants at Week 489
Number of Participants at Week 7210
SecondaryNumber of Participants With Clinical Laboratory Abnormalities

Protocol-required safety laboratory assessments include: Lymphocytes \<0.8 × LLN; Neutrophils \<0.8 × LLN, or \>1.2 × ULN; Basophils \>1.2 × ULN; Activated Partial Thromboplastin Time \>1.1 × ULN; Prothrombin Time \>1.1 × ULN; Prothrombin International Normalized Ratio \>1.1 × ULN; Bilirubin \>1.5 × ULN; Urate \> 1.2 × ULN; Cholesterol \>1.3 × ULN; Potassium \<0.9 × LLN; Phosphate \>1.2 × ULN; Bicarbonate \>1.1 × ULN; Thyroid Stimulating Hormone \>1.2 × ULN; URINE Protein ≥1; URINE Hemoglobin ≥1; Nitrite ≥1; URINE Erythrocytes ≥20; Epithelial Cells ≥6; and Casts \>1.

Time frame:
Baseline up to Week 72
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities
ParticipantsTafamidis Meglumine 20 mg Once Daily (QD)
Number of Participants With Clinical Laboratory Abnormalities12
SecondaryTransthyretin (TTR) Concentrations on Day 1 (Baseline), and at Weeks 8, 12, 24, 48, and 72

The TTR (also referred to as pre-albumin) concentrations were determined as pharmacodynamic (PD) biomarkers.

Time frame:
Baseline, Weeks 8, 12, 24, 48, and 72
Reported as:
Median · Milligrams per deciliter (mg/dL)
Transthyretin (TTR) Concentrations on Day 1 (Baseline), and at Weeks 8, 12, 24, 48, and 72
Milligrams per deciliter (mg/dL)Tafamidis Meglumine 20 mg Once Daily (QD)
Median and Range of TTR Concentration on Day 1 (baseline)18.70 (9.03 to 28.0)
Median and Range of TTR Concentration at Week 823.20 (13.5 to 36.2)
Median and Range of TTR Concentration at Week 1228.00 (13.5 to 33.3)
Median and Range of TTR Concentration at Week 2425.70 (13.3 to 30.9)
Median and Range of TTR Concentration at Week 4827.90 (19.0 to 33.4)
Median and Range of TTR Concentration at Week 7226.60 (14.4 to 32.2)
SecondaryTTR Stabilization and Percentage and 95% CI of Responders in TTR Stabilization at Post Baseline Visit

The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration (post-denaturation) to the measured TTR concentration (pre-denaturation). Percent Stabilization (%) is the difference between the dosed FOI and the baseline FOI expressed as a percentage of the baseline FOI. Responder was the participant who achieved TTR stabilization (ie, who had been TTR stabilized). Percentage of responders was number of responders / number of evaluable (i.e., analyzed) participants.

Time frame:
Weeks 8, 12, 24, 48, and 72
Reported as:
Number · Percentage of participants
TTR Stabilization and Percentage and 95% CI of Responders in TTR Stabilization at Post Baseline Visit
Percentage of participantsTafamidis Meglumine 20 mg Once Daily (QD)
Percentage and 95% CI of Responders in TTR Stabilization at Week 8100.0 (66.4 to 100.0)
Percentage and 95% CI of Responders in TTR Stabilization at Week 12100.0 (69.2 to 100.0)
Percentage and 95% CI of Responders in transthyretin (TTR) Stabilization at Week 24100.0 (69.2 to 100.0)
Percentage and 95% CI of Responders in transthyretin (TTR) Stabilization at Week 48100.0 (54.1 to 100.0)
Percentage and 95% CI of Responders in transthyretin (TTR) Stabilization at Week 7287.5 (47.3 to 99.7)

Adverse events

Collected over Baseline up to Week 77. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tafamidis Meglumine 20 mg Once Daily (QD)0/15 (0%)3/15 (20%)13/15 (86.7%)
Most frequent serious events
Most frequent serious events
EventTafamidis Meglumine 20 mg Once Daily (QD)
AmyloidosisImmune system disorders1/15
Femur fractureInjury, poisoning and procedural complications1/15
Orthostatic hypotensionVascular disorders1/15
Most frequent other events
Showing 10 of 51
Most frequent other events
EventTafamidis Meglumine 20 mg Once Daily (QD)
Upper respiratory tract infectionInfections and infestations3/15
Urinary tract infectionInfections and infestations3/15
FallInjury, poisoning and procedural complications3/15
AnaemiaBlood and lymphatic system disorders2/15
DiarrhoeaGastrointestinal disorders2/15
Blood thyroid stimulating hormone decreasedInvestigations2/15
Urinary sediment presentInvestigations2/15
White blood cells urine positiveInvestigations2/15
HypertriglyceridaemiaMetabolism and nutrition disorders2/15
HyperuricaemiaMetabolism and nutrition disorders2/15

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tafamidis Meglumine 20 mg Once Daily (QD)
Mean51.1 ± 15.75
Age, Customized
Age, Customized(Participants)Tafamidis Meglumine 20 mg Once Daily (QD)
18-44 years6
45-64 years5
>=65 years4
Sex: Female, Male
Sex: Female, Male(Participants)Tafamidis Meglumine 20 mg Once Daily (QD)
Female5
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tafamidis Meglumine 20 mg Once Daily (QD)
Hispanic or Latino0
Not Hispanic or Latino15
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tafamidis Meglumine 20 mg Once Daily (QD)
Asian15
08

Study locations

9 sites
  • Peking University First Hospital
    Beijing, Beijing 100034, China
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
  • NanFang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Huashan Hospital Fudan University
    Shanghai, Shanghai 200040, China
  • Peking union hospital of Chinese academy of medical sciences
    Beijing, 100005, China
  • Xuanwu Hospital Capital Medical University
    Beijing, 100053, China
  • Tiantan Hospital Capital Medical University
    Beijing, 100070, China
  • Peking union hospital of Chinese academy of medical sciences
    Beijing, 100730, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Feb 2023, 21 months.

Results were first posted in Mar 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2021
First posted
Apr 2, 2021
StartActual
Apr 28, 2021
Primary completionActual
Feb 12, 2023
CompletionActual
Feb 12, 2023
Results first posted
Mar 12, 2024
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04828993
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 2, 2021
Start date
Apr 28, 2021
Primary completion
Feb 12, 2023
Completion
Feb 12, 2023
Results posted
Mar 12, 2024
Last update
Mar 12, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafamidis

Start the discussion